NicOx.... in attesa di.....

[elfrancese]

KEPLER inchangé à 10E

 

[viralic]

KEPLER inchangé à 10E

navi1

13:57

Effectivement : Vendredi 17 3 pronostics >>> jeudi 23 : 2 pile dans le mille !!!!!!!
A quand le resultat du 3° ?
Et on nous dira qu'il n'y a pas de fuite ou d'initiés chez Nicox ?????


puoi dire ai tuoi amici francesi di evitare di fare battute ......non ho informazioni da nessuno, solo esperienze personali dovuto al fatto che seguo nicox da quasi 20 anni. Era evidente che le notizie sulla blefarite non erano ottime, o avrebbero fatto immediatamente ai primi di settembre un annuncio.....in secondo luogo il ritardo era nell'aria già da parecchi mesi in quanto il reclutamento non è ancora arrivato a percentuali che permettono di avere i dati entro maggio giugno come previsto....non ci vuole un genio e neppure una informazione riservata......ti prego di farli smettere , grazie. Riguardo alla terza previsione...non escudo che ci possa anche essere un ak...ma sarebbe un suicidio per i managers farlo ora con lo sconto vuol dire 2,50 euro...neppure gli conviene, raccolgono 4 soldi e diluiscono un sacco......se hanno la possibiità di avere altro credito grazie al buon andamento di vendite del vyzulta e dello Zerviate, penso che opteranno su quello.....almeno me lo auguro...o finiamo sotto i 2 euro....non trovi ?
p.s visto che io non scrivo su boursorama, se dovessi fare altre previsioni per il futuro azzeccate oppure sbagliate che siano su nicox, ti chiedo cortesemente di non divulgarle sul forum francese....la maggior parte è solo una manica di idioti ( scusami ma sono sincero) che continua ad inveire e non portano nulla di utile tranne rare eccezioni.

 

[elfrancese]

En effet il faut que tu comprennes qu’il y a beaucoup de personnes qui souhaitent la ruine de Nicox en se déclarant pourtant actionnaire … c’est très triste

 

[elfrancese]

je sais trés bien que

tes predictions sont liés à ta connaissance du dossier depuis des années et des années

la preuve que tu n'as pas des dons divinatoires est que tu nous annoncais trés souvent un rachat d'ocumension l'année dernière...

 

[viralic]

Anzi devi capire che sono tante le persone che augurano la rovina di Nicox dichiarandosi azionista… è molto triste
[/CITAZIONE]

Lo so benissimo

le tue previsioni sono state legate alla tua conoscenza del caso per anni e anni

la prova che non hai doti divinatorie è che molto spesso hai annunciato un riscatto di documentazioni l'anno scorso...
[/CITAZIONE]

esatto....a volte posso azzeccare le previsioni, purtroppo a volte le sbaglio in pieno...avessi informazioni dirette non avrei perso soldi in questa azione.

 

[viralic]

ho scritto che spero non ci sarà un nuovo ak...poi magari il mese prossimo arriva una nuova diluizione smentendo completamente la mia previsione...di certo nicox ha cassa sino alla fine del 2022 , vuol dire che prima o poi deve far entrare nuovo cash o non ci arriva al termine della fase montblanc....è avere informazioni privilegiate questo ?....non mi pare visto che è stato dichiarato dalla società chiaramente....io mi auguro che non ci sia un nuovo ak fortemente diluitivo a questi prezzi , ma se la società non avrà altro modo di ottenere cash è chiaro che sarà inevitabile.......

 

[elfrancese]

honnetement, si Nicox a bon espoir pour NCX470 d'etre best in class incontesté, cela ne me poserait pas de probleme...
il faut qu'ils apprennent à communiquer positivement sur les atouts !

Vu le timing, si cette AK amene des actionnaires qui souhaitent beneficier du succés de mont blanc en restant au capital jusque ce jalon décisif puis aprés, cela peut mener le rebond rapide
je ne veux pas de fond anglo saxons qui revendent le mois suivant !
si HBM se renforce, cela pourrait etre aussi positif etant donné qu'ils meriteraient eux de pouvoir entrer trés bas en raison de leur fidelité ...

mais... je préférerais un pret naturellement..

 

[PIZZODIGINO]

Guly, dove sei ? Sei in ferie ?

 

[elfrancese]

Direction 3 euro

 

[viralic]

Press Release

Nicox First Half 2021 Financial Results and Business Update

H1 2021 net revenue1 of €1.3 million and cash position of €36.5 million NCX 470 NDA submission remains on track September 27, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported the financial results for Nicox SA and its subsidiaries (the “Nicox Group”) for the six months ending June 30, 2021 and provided an update on recent events as well as progress on key programs. First Half 2021 Financial Highlights Net revenue1 for the first half of 2021 was €1.3 million (including €1.2 million in royalty revenue) versus €2.4 million (including €1.4 million in royalty revenue) for the first half of 2020. Operating expenses for the first half of 2021 were €13.3 million compared to €10.2 million for the first half of 2020. The Nicox Group recorded a net loss of €11.7 million for the six months ended June 30, 2021, compared to a net loss of €14.6 million for the same period in 2020. As of June 30, 2021, the Nicox Group had cash and cash equivalents of €36.5 million, as compared with €42.0 million at March 31, 2021 and €47.2 million at December 31, 2020. The Company is financed for at least 12 months, based on the development of NCX 470 alone. As of June 30, 2021, the Nicox Group had financial debt of €18.0 million consisting of €16.0 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a €2 million credit agreement guaranteed by the French State and granted in August 2020 in the context of the COVID-19 pandemic. Details of the bond financing agreement can be found in the Press Release of January 29, 2021. Recent Events The Mississippi Phase 2b clinical trial of NCX 4251 ophthalmic suspension 0.1%, evaluated against placebo, while not meeting the pre-defined blepharitis primary endpoint, demonstrated statistically significant results on blepharitis signs and symptoms when measured as change from baseline. NCX 4251 was found to be safe and well-tolerated over 14 days’ treatment, with no serious adverse events (see Press Release of September 23, 2021). VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, recently received regulatory approval in Brazil, Jordan and Singapore. Further approvals and launches of VYZULTA will now be reported by our global partner Bausch + Lomb on a quarterly basis. Dr. José Boyer has retired as Interim Head of R&D, although he will continue to advise the Company as a consultant. We would like to thank him for his commitment and contribution to Nicox. Fera’s resubmitted application for Orphan Drug Designation (ODD) for naproxcinod in sickle-cell disease has been refused by the U.S. Food and Drug Administration (FDA), and Fera is currently seeking to discuss the next steps with the FDA. Fera continues to review other undisclosed therapeutic indications for naproxcinod. Key Programs Updates NCX 470: The New Drug Application submission timing to the U.S. FDA remains in line with our expectations, driven by the end of 2023 date for results from the ongoing Denali Phase 3 clinical trial. In the first Phase 3 clinical trial, Mont Blanc, 494 out of 670 patients (74%) had been randomized as of September 20, and 398 of those patients have completed the 3-month efficacy evaluation. Given recruitment continues to be impacted by COVID-19, we are prudently moving the expectation for Mont Blanc trial top-line results to Q1 2023 (previously Q2 2022). The Phase 3 program, evaluating NCX 470 for lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, is expected to support NDA submissions in the U.S. and China, and will also provide data for countries accepting the same package for approval. NCX 4251: Following the results of the Phase 2b Mississippi trial, the Company plans to meet with the U.S. FDA in early 2022 to discuss next steps in the development of this innovative product candidate for blepharitis. ZERVIATETM in China: A Phase 3 clinical trial intended to support an application for regulatory approval in China, conducted and financed by our partner Ocumension, is ongoing. Only figures at December 31, 2020 are audited, all other figures of this press release are non-audited. Notes Net revenue consists of revenue from collaborations less royalty payments which we refer to as net profit from collaborations in the condensed consolidated statements of profit or loss for the six-month period ended June 30, 2021.